Danielle K. Boyd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danielle K. Boyd has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ahida Batrouney
Department of Anatomical Pathology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
45 shared publications - Ariena J. Kersbergen
ACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
45 shared publications - Christine Khoo
Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
45 shared publications - David J. Byrne
Peter MacCallum Cancer Centre
45 shared publications - Jin Ng
The Walter and Eliza Hall Institute of Medical Research 2 ACRF Cancer Biology and Stem Cells Division Parkville, Australia
45 shared publications - John Dorrance Minna
Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA
45 shared publications
Latest Publications
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
List of cell lines from Figure 1D and their NE-score.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
List of cell lines from Figure 1D and their NE-score.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure 5 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
YAP1 is expressed in SMARCA4-UT primary samples. A, Unsupervised hierarchical clustering, based on a SCLC-specific YAP1 signature (n = 49 genes) identified by Pearsall and colleagues (10), was performed on SCCOHT and lung carcinoma samples [cell lines from the CCLE and bulk-RNA sequenced patient samples from Le Loarer and colleagues (24)]. Cell lines that cluster with the SMARCA4-UT samples are highlighted in the gray box. B, YAP1 IHC on SCLC-A/N/P and SMARCA4-mutant cell line xenografts. Scale bar = 100 μm. C, H&E, SMARCA4, and YAP1 IHC in primary SMARCA4-UT samples (n = 6) together with an SCLC patient sample. Scale bar = 100 μm.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
YAP1 is expressed in SMARCA4-UT primary samples. A, Unsupervised hierarchical clustering, based on a SCLC-specific YAP1 signature (n = 49 genes) identified by Pearsall and colleagues (10), was performed on SCCOHT and lung carcinoma samples [cell lines from the CCLE and bulk-RNA sequenced patient samples from Le Loarer and colleagues (24)]. Cell lines that cluster with the SMARCA4-UT samples are highlighted in the gray box. B, YAP1 IHC on SCLC-A/N/P and SMARCA4-mutant cell line xenografts. Scale bar = 100 μm. C, H&E, SMARCA4, and YAP1 IHC in primary SMARCA4-UT samples (n = 6) together with an SCLC patient sample. Scale bar = 100 μm.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Comparison of sequencing data between CCLE and UTSW.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Comparison of sequencing data between CCLE and UTSW.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure 5 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
YAP1 is expressed in SMARCA4-UT primary samples. A, Unsupervised hierarchical clustering, based on a SCLC-specific YAP1 signature (n = 49 genes) identified by Pearsall and colleagues (10), was performed on SCCOHT and lung carcinoma samples [cell lines from the CCLE and bulk-RNA sequenced patient samples from Le Loarer and colleagues (24)]. Cell lines that cluster with the SMARCA4-UT samples are highlighted in the gray box. B, YAP1 IHC on SCLC-A/N/P and SMARCA4-mutant cell line xenografts. Scale bar = 100 μm. C, H&E, SMARCA4, and YAP1 IHC in primary SMARCA4-UT samples (n = 6) together with an SCLC patient sample. Scale bar = 100 μm.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
YAP1 is expressed in SMARCA4-UT primary samples. A, Unsupervised hierarchical clustering, based on a SCLC-specific YAP1 signature (n = 49 genes) identified by Pearsall and colleagues (10), was performed on SCCOHT and lung carcinoma samples [cell lines from the CCLE and bulk-RNA sequenced patient samples from Le Loarer and colleagues (24)]. Cell lines that cluster with the SMARCA4-UT samples are highlighted in the gray box. B, YAP1 IHC on SCLC-A/N/P and SMARCA4-mutant cell line xenografts. Scale bar = 100 μm. C, H&E, SMARCA4, and YAP1 IHC in primary SMARCA4-UT samples (n = 6) together with an SCLC patient sample. Scale bar = 100 μm.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
26 mutated genes unique to SCLC-Y cell lines.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
26 mutated genes unique to SCLC-Y cell lines.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
26 mutated genes unique to SCLC-Y cell lines.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
26 mutated genes unique to SCLC-Y cell lines.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure 3 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Distinct immunophenotype of SMARCA4-mutant compared with SMARCA4-WT SCLC cell lines. Representative IHC images of SMARCA4, synaptophysin (SYN), CD56, TTF1, INSM1, and RB1 in SMARCA4-WT, NE-high SCLC cell line (H1092) compared with SMARCA4-mutant SCLC cell lines. Scale bar = 100 μm.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Distinct immunophenotype of SMARCA4-mutant compared with SMARCA4-WT SCLC cell lines. Representative IHC images of SMARCA4, synaptophysin (SYN), CD56, TTF1, INSM1, and RB1 in SMARCA4-WT, NE-high SCLC cell line (H1092) compared with SMARCA4-mutant SCLC cell lines. Scale bar = 100 μm.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
SMARCA4-UT cell lines and patient samples based on unsupervised hierarchical clustering using YAP1 signature genes.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
SMARCA4-UT cell lines and patient samples based on unsupervised hierarchical clustering using YAP1 signature genes.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure 3 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Distinct immunophenotype of SMARCA4-mutant compared with SMARCA4-WT SCLC cell lines. Representative IHC images of SMARCA4, synaptophysin (SYN), CD56, TTF1, INSM1, and RB1 in SMARCA4-WT, NE-high SCLC cell line (H1092) compared with SMARCA4-mutant SCLC cell lines. Scale bar = 100 μm.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Distinct immunophenotype of SMARCA4-mutant compared with SMARCA4-WT SCLC cell lines. Representative IHC images of SMARCA4, synaptophysin (SYN), CD56, TTF1, INSM1, and RB1 in SMARCA4-WT, NE-high SCLC cell line (H1092) compared with SMARCA4-mutant SCLC cell lines. Scale bar = 100 μm.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
SMARCA4-UT cluster validation.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
SMARCA4-UT cluster validation.